Advertisement

Elevated CA 15.3 in Newly Diagnosed Breast Cancer: A Retrospective Study

Published:April 29, 2022DOI:https://doi.org/10.1016/j.clbc.2022.04.007

      Abstract

      Purpose

      To examine the relationship between baseline elevated CA 15.3 (>30 kU/L) and the prevalence of primary or secondary metastatic disease in breast cancer.

      Methods

      We performed a retrospective, single-center cohort study on patients with newly diagnosed breast cancer and baseline CA 15.3> 30 kU/L, diagnosed between 2000-2015. Information on tumor characteristics, pre-treatment CA 15.3, staging results, treatment approach, disease recurrence and death were collected from individual medical files. For every tumor subtype, the optimal cut-off value of CA 15.3 for determining primary metastatic disease is determined.

      Results

      Eight hundred ninety-four patients with baseline CA15.3 > 30 kU/L were included of which 38% were diagnosed with primary metastatic disease while 15% subsequently developed secondary metastatic disease, with a median follow-up of 74 months. LuminalHER2 tumors had the highest proportion of primary metastatic disease (48%), Triple Negative tumors had the highest proportion of secondary metastatic disease (24%) (p=0.008). A higher CA 15.3 value corresponds to higher risk of both primary and secondary metastatic disease (p<0.001). For the determination of primary metastatic disease, optimal cut-off values for CA 15.3 range between 44 kU/L (Triple Negative) and 59 kU/L (Luminal B).

      Conclusion

      In patients with newly diagnosed breast cancer and baseline elevated CA 15.3>30 kU/L, 38% presents with primary metastatic disease and 15% develops secondary metastatic disease, with a median follow-up of 74 months. Our results can help clinicians to identify patients at risk of primary or secondary metastatic disease via information on tumor subtype and baseline CA 15.3.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Belgian Cancer Registry, Cancer burden in Belgium 2004-2017. Brussels, 2020.

        • Duffy MJ
        • McDermott EW
        • Crown J
        Blood-based biomarkers in breast cancer: from proteins to circulating tumor cells to circulating tumor DNA.
        Tumor Biol. 2018; https://doi.org/10.1177/1010428318776169
        • Duffy MJ
        • Evoy D
        • McDermott EW
        CA 15-3: Uses and limitation as a biomarker for breast cancer.
        Clinica Chimica Acta. 2010; https://doi.org/10.1016/j.cca.2010.08.039
        • Hattrup CL
        • Gendler SJ
        Structure and function of the cell surface (tethered) mucins.
        Annual Rev Physiol. 2008; https://doi.org/10.1146/annurev.physiol.70.113006.100659
        • Kufe DW
        Mucins in cancer: function, prognosis and therapy.
        Nat Rev Cancer. 2009; https://doi.org/10.1038/nrc2761
        • Harris LN
        • Ismaila N
        • McShane LM
        • et al.
        Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of clinical Oncology clinical practice guideline.
        J Cli Oncol. 2016; https://doi.org/10.1200/JCO.2015.65.2289
        • Khatcheressian JL
        • Hurley P
        • Bantug E
        • et al.
        Breast cancer follow-up and management after primary treatment: American society of clinical oncology clinical practice guideline update.
        J Clin Oncol. 2013; https://doi.org/10.1200/JCO.2012.45.9859
        • Harris L.
        • Fritsche H.
        • Mennel R.
        • Norton L.
        • Ravdin P.
        • Taube S.
        • Bast R.C.
        American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
        J Clin Oncol. 2007; https://doi.org/10.1200/JCO.2007.14.2364
      2. NCCN Clinical Practice Guidelines in Oncology, Breast cancer, version 2.2022, 2021. Available at: www.nccn.org

        • Henry L.N.
        • Hayes D.F.
        • Ramsey S.D.
        • Hortobagyi G.N.
        • Barlow W.E.
        • Gralow J.R.
        Promoting quality and evidence-based care in early-stage breast cancer follow-up.
        J Nat Cancer Inst. 2014; https://doi.org/10.1093/jnci/dju034
        • Li X
        • Dai D
        • Chen B
        • Tang H
        • Xie X
        • Wei W
        Clinicopathological and prognostic significance of cancer antigen 15-3 and carcinoembryonic antigen in breast cancer: a meta-analysis including 12,993 patients.
        Dis Markers. 2018; https://doi.org/10.1155/2018/9863092
        • Sandri MT
        • Salvatici M
        • Botteri E
        • et al.
        Prognostic role of CA15.3 in 7942 patients with operable breast cancer.
        Breast Cancer Res Treat. 2012; https://doi.org/10.1007/s10549-011-1863-x
        • Brouckaert O
        • Laenen A
        • Wildiers H
        • et al.
        The prognostic role of preoperative and (early) postoperatively change in CA15.3 serum levels in a single hospital cohort of primary operable breast cancers.
        Breast. 2013; https://doi.org/10.1016/j.breast.2013.02.021
        • Nam S
        • Lim W
        • Jeong J
        • et al.
        The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry.
        Breast Cancer Res Treat. 2019; https://doi.org/10.1007/s10549-019-05357-y
        • Myers RE
        • Johnston M
        • Pritchard K
        • et al.
        Baseline staging tests in primary breast cancer: a practice guideline.
        CMAJ. 2001;
        • De Cock L
        • Heylen J
        • Wildiers A
        • Punie K
        • Smeets A
        • Weltens C
        • et al.
        Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3.
        ESMO Open [Internet]. 2021; 6100203https://doi.org/10.1016/j.esmoop.2021.100203
        • Goldhirsch A
        • Wood WC
        • Coates AS
        • Gelber RD
        • Thürlimann B
        • Senn HJ
        Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011.
        Ann Oncol. 2011; 22: 1736-1747https://doi.org/10.1093/annonc/mdr304
        • Fluss R
        • Faraggi D
        • Reiser B
        Estimation of the Youden Index and its associated cutoff point.
        Biometrical J. 2005; https://doi.org/10.1002/bimj.200410135
        • Kokko R
        • Hakama M
        • Holli K
        Follow-up cost of breast cancer patients with localized disease after primary treatment: a randomized trial.
        Breast Cancer Res Treat. 2005;
        • Joseph E
        • Hyacinthe M
        • Lyman GH
        • et al.
        Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer.
        Ann Surg Oncol. 1998;
        • Molina R
        • Barak V
        • Van Dalen A
        • et al.
        Tumor markers in breast cancer - European group on tumor markers recommendations.
        Tumor Biol. 26. 2005: 281-293
        • Van Mechelen M
        • Van Herck A
        • Punie K
        • et al.
        Behavior of metastatic breast cancer according to subtype.
        Breast Cancer Res Treat. 2020; 181: 115-125https://doi.org/10.1007/s10549-020-05597-3
        • Gonssaud B
        • Goussot V
        • Berriolo-Riedinger A
        • et al.
        Intérêt clinique du CA 15-3 pour la détection des métastases des cancers du sein nouvellement diagnostiqués.
        Annales de Biologie Clinique. 2017; 75: 421-429https://doi.org/10.1684/abc.2017.1257
        • Van Der Vegt B
        • De Roos MAJ
        • Peterse JL
        • et al.
        The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
        Histopathology. 2007; 51: 322-335https://doi.org/10.1111/j.1365-2559.2007.02757.x
        • Cardoso F
        • Kyriakides S
        • Ohno S
        • et al.
        Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2019; 30: 1194-1220https://doi.org/10.1093/annonc/mdz173
        • Pan H
        • Gray R
        • Braybrooke J
        • et al.
        20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years.
        New England J Med. 2017; https://doi.org/10.1056/nejmoa1701830
        • Li X
        • Xu Y
        • Zhang L
        Serum CA153 as biomarker for cancer and noncancer diseases.
        Progress Mol Biol Transl Sci. 2019; https://doi.org/10.1016/bs.pmbts.2019.01.005